echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Two major products of Yuanda Pharmaceutical have achieved milestone progress

    Two major products of Yuanda Pharmaceutical have achieved milestone progress

    • Last Update: 2021-05-02
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 19, 2021, Broad Pharmaceuticals announced that, as a research and development platform in the field of tumor immunotherapy and DNA technology of Broad Pharmaceuticals, OncoSec Medical Incorporated (OncoSec, an associate company of Broad Pharmaceuticals) developed by the US Nasdaq-listed company GenPulse™, a new generation of gene electroporation equipment, recently obtained the European Union CE certification.


    At the same time, Grand Pharmaceuticals announced that its wholly-owned subsidiary Grand Medical Pty Ltd (the company’s innovative drug research and development center in Australia) is developing a global innovative drug STC3141 for the field of severe infections.


    The new generation of gene transfer equipment GenPulse™

    The new generation of gene electrotransformation equipment GenPulse™ The new generation of gene electrotransformation equipment GenPulse™

    OncoSec is a high-tech innovative biotechnology company that has entered the clinical stage.


    The GenPulse™, which has obtained the EU CE certification this time, is part of the OMS electroporation device platform and is used for the treatment of solid tumors.


    GenPulse™'s CE certification is an important milestone for OncoSec’s commercialization in Europe.


    Innovative drug STC3141

    Innovative drug STC3141 Innovative drug STC3141

    There are few therapeutic drugs with definite curative effect for sepsis.


    According to Broad Pharmaceuticals, this time STC3141 was approved to carry out a phase IIa clinical study of new coronary pneumonia in Belgium.


    As the headquarters of the European Union, Belgium is an important research and development place for the global treatment of disease drugs and the world's second largest exporter of drugs.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.